Cardiff Oncology (CRDF) Return on Sales (2011 - 2026)
Cardiff Oncology (CRDF) posted Return on Sales of 2.65% for Q4 2025, down 164.95% sequentially from 1.0% in Q3 2025, and down 110.0% YoY from 26.53% in Q4 2024.
Cardiff Oncology (CRDF) Return on Sales (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Return on Sales for 15 years, with the latest figure at 2.65% in Q4 2025.
- Quarterly Return on Sales fell 110.0% year-over-year to 2.65% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.91% (down 76.0% YoY) and the FY2025 annual result came in at 1.74%, down 37.0% from the prior year.
- Return on Sales eased to 2.65% in Q4 2025 per CRDF's latest filing, from 1.0% in the prior quarter.
- Over five years, Return on Sales peaked at 0.72% in Q3 2023 and troughed at 3.11% in Q4 2023.
- A 5-year average of 1.52% and a median of 1.51% in 2022 frame the typical range for Return on Sales.
- The sharpest annual moves came in 2023 and 2024: Return on Sales sank 236 bps in 2023, then surged 156 bps in 2024.
- Over 5 years, Return on Sales stood at 0.73% in 2021, then decreased by 2 bps to 0.75% in 2022, then slumped by 316 bps to 3.11% in 2023, then surged by 50 bps to 1.55% in 2024, then sank by 71 bps to 2.65% in 2025.
- According to Business Quant data, Return on Sales over the past three periods registered 2.65%, 1.0%, and 1.55% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -0.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.89% |
| Dec 31, 2025 | -2.65% |
| Sep 30, 2025 | -1.00% |
| Jun 30, 2025 | -1.55% |
| Mar 31, 2025 | -1.66% |
| Dec 31, 2024 | -1.55% |
| Sep 30, 2024 | -0.87% |
| Jun 30, 2024 | -0.79% |
| Mar 31, 2024 | -1.36% |
| Dec 31, 2023 | -3.11% |
| Sep 30, 2023 | -0.72% |
| Jun 30, 2023 | -1.29% |
| Mar 31, 2023 | -1.50% |
| Dec 31, 2022 | -0.75% |
| Sep 30, 2022 | -1.05% |
| Jun 30, 2022 | -1.53% |
| Mar 31, 2022 | -1.99% |
| Dec 31, 2021 | -0.73% |
| Sep 30, 2021 | -1.69% |
| Jun 30, 2021 | -2.11% |